Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss of $1.87/Share

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q2 EPS of ($1.87), versus ($13.34) reported last year.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Daqo New Energy (DQ) Misses Q2 EPS by 67c
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance